Adicet Bio (ACET) News Today $0.75 +0.04 (+6.19%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACET Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Consensus PT from BrokeragesMay 20 at 1:40 AM | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have received a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the coMay 19 at 4:19 AM | marketbeat.comAdicet Bio (NASDAQ:ACET) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of Adicet Bio in a research note on Friday. They issued a "hold" rating for the company.May 18 at 2:29 AM | marketbeat.comAdicet Bio (NASDAQ:ACET) Now Covered by Analysts at StockNews.comMay 16, 2025 | americanbankingnews.comWedbush Has Bullish Forecast for Adicet Bio Q3 EarningsMay 11, 2025 | americanbankingnews.comAdicet Bio (ACET) to Release Earnings on TuesdayAdicet Bio (NASDAQ:ACET) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-adicet-bio-inc-stock/)May 8, 2025 | marketbeat.comAdicet Bio Stock Price, Quotes and Forecasts | NASDAQ:ACET | BenzingaMay 8, 2025 | benzinga.comAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 6, 2025 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Short Interest UpdateAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 2,060,000 shares, a decline of 27.7% from the March 31st total of 2,850,000 shares. Approximately 3.1% of the company's shares are sold short. Based on an average daily trading volume, of 796,900 shares, the short-interest ratio is presently 2.6 days.May 3, 2025 | marketbeat.comAdicet Bio (NASDAQ:ACET) Upgraded at StockNews.comStockNews.com upgraded shares of Adicet Bio from a "sell" rating to a "hold" rating in a report on Monday.April 30, 2025 | marketbeat.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 30, 2025 | businesswire.comAdicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingApril 28, 2025 | businesswire.comWe're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn RateApril 27, 2025 | finance.yahoo.com12 Health Care Stocks Moving In Thursday's After-Market SessionApril 18, 2025 | benzinga.comAdicet Bio Appoints Michael Grissinger to the Board of DirectorsApril 17, 2025 | finance.yahoo.comAdicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual ConferenceMarch 31, 2025 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy raMarch 29, 2025 | marketbeat.comAdicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comAdicet Bio (NASDAQ:ACET) Receives "Buy" Rating from GuggenheimGuggenheim restated a "buy" rating and issued a $7.00 price target on shares of Adicet Bio in a report on Friday.March 22, 2025 | marketbeat.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 16.9%Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,140,000 shares, a decrease of 16.9% from the February 13th total of 3,780,000 shares. Based on an average trading volume of 834,000 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.7% of the company's stock are sold short.March 18, 2025 | marketbeat.comAdicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal yearMarch 14, 2025 | investing.comRegeneron Pharmaceuticals Inc. Makes New $931,000 Investment in Adicet Bio, Inc. (NASDAQ:ACET)Regeneron Pharmaceuticals Inc. purchased a new stake in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 968,183 shares of the company's stock, valued at approximatMarch 11, 2025 | marketbeat.comAdicet Bio (ACET) Expected to Announce Earnings on TuesdayAdicet Bio (NASDAQ:ACET) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Adicet Bio (ACET)March 10, 2025 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Receives "Neutral" Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Adicet Bio in a research note on Friday.March 8, 2025 | marketbeat.comAdicet Bio (NASDAQ:ACET) Issues Earnings ResultsAdicet Bio (NASDAQ:ACET - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05.March 7, 2025 | marketbeat.comAdicet Bio reports Q4 EPS (32c), consensus (35c)March 6, 2025 | markets.businessinsider.comAdicet Bio files $250M mixed securities shelfMarch 6, 2025 | markets.businessinsider.comAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 6, 2025 | businesswire.comAdicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific MeetingMarch 3, 2025 | finance.yahoo.comAdicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by AnalystsShares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy ratingMarch 3, 2025 | marketbeat.comAdicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "neutral" rating on shares of Adicet Bio in a research note on Thursday.February 28, 2025 | marketbeat.comAdicet Bio shares rise on FDA Fast Track Designation for ADI-001February 27, 2025 | finance.yahoo.comAdicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)February 27, 2025 | businesswire.comAdicet Bio granted fast track designation for ADI-001 by FDAFebruary 6, 2025 | markets.businessinsider.comAdicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by BrokeragesAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and three have given a buy recommeFebruary 6, 2025 | marketbeat.comAdicet Bio's (ACET) Market Perform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Adicet Bio in a research report on Thursday.February 6, 2025 | marketbeat.comAdicet Bio's (ACET) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a report on Wednesday.February 5, 2025 | marketbeat.comAdicet Bio Gets Fast Track Designation For ADI-001 In Refractory Systemic Lupus ErythematosusFebruary 5, 2025 | markets.businessinsider.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 31, 2025 | businesswire.comAdicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | finance.yahoo.comAdicet Bio Provides Corporate Update and Highlights Expected 2025 MilestonesJanuary 8, 2025 | businesswire.comAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)December 31, 2024 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Sees Large Increase in Short InterestAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 3,350,000 shares, a growth of 12.0% from the November 30th total of 2,990,000 shares. Based on an average daily volume of 598,300 shares, the days-to-cover ratio is presently 5.6 days.December 30, 2024 | marketbeat.comAdicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average - Time to Sell?Adicet Bio (NASDAQ:ACET) Stock Crosses Below 200-Day Moving Average - Here's WhyDecember 28, 2024 | marketbeat.comH.C. Wainwright Remains a Hold on Adicet Bio (ACET)December 23, 2024 | markets.businessinsider.comAdicet Bio says 1st patient dosed in Phase1 trial of ADI-270 to treat ccRCCDecember 20, 2024 | markets.businessinsider.comAdicet Bio's (ACET) Neutral Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Adicet Bio in a report on Thursday.December 19, 2024 | marketbeat.comAdicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaDecember 19, 2024 | finance.yahoo.comAdicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal yearDecember 19, 2024 | uk.investing.com Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Media Mentions By Week ACET Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACET News Sentiment▼0.300.65▲Average Medical News Sentiment ACET News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACET Articles This Week▼42▲ACET Articles Average Week Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GWW News FAST News URI News WSO News AIT News WCC News BECN News AL News GATX News MSM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACET) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACET Stock Free ACET Stock Alerts